Difference between revisions of "Breast cancer, BRCA-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 11: Line 11:
 
*'''2011:''' [http://annonc.oxfordjournals.org/content/22/suppl_6/vi31.full.pdf+html BRCA in breast cancer: ESMO Clinical Practice Guidelines] [https://www.ncbi.nlm.nih.gov/pubmed/21908500 PubMed]
 
*'''2011:''' [http://annonc.oxfordjournals.org/content/22/suppl_6/vi31.full.pdf+html BRCA in breast cancer: ESMO Clinical Practice Guidelines] [https://www.ncbi.nlm.nih.gov/pubmed/21908500 PubMed]
  
−
=Metastatic disease, all lines of therapy=
+
=Advanced or metastatic disease, all lines of therapy=
 
==Olaparib monotherapy {{#subobject:a019cd|Regimen=1}}==
 
==Olaparib monotherapy {{#subobject:a019cd|Regimen=1}}==
 
{| class="wikitable" style="float:right; margin-left: 5px;"
 
{| class="wikitable" style="float:right; margin-left: 5px;"
Line 29: Line 29:
 
*[[Olaparib (Lynparza)]] 100 mg PO BID
 
*[[Olaparib (Lynparza)]] 100 mg PO BID
  
−
'''Continued until progression'''
+
'''Continued indefinitely'''
  
 
===Variant #2, 300 mg BID {{#subobject:3b0774|Variant=1}}===
 
===Variant #2, 300 mg BID {{#subobject:3b0774|Variant=1}}===
Line 66: Line 66:
 
*[[Olaparib (Lynparza)]] 400 mg PO BID
 
*[[Olaparib (Lynparza)]] 400 mg PO BID
  
−
'''Continued until progression'''
+
'''Continued indefinitely'''
  
 
===References===
 
===References===
Line 73: Line 73:
 
# Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [http://jco.ascopubs.org/content/33/3/244.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25366685 PubMed]
 
# Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [http://jco.ascopubs.org/content/33/3/244.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25366685 PubMed]
 
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [http://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]
 
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [http://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]
 +
 +
==Talazoparib monotherapy {{#subobject:bb55eb|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:06a5b4|Variant=1}}===
 +
{| class="wikitable" style="color:white; background-color:#404040"
 +
|<small>'''FDA-recommended dose'''</small>
 +
|-
 +
|}
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 25%"|Comparator
 +
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 +
|-
 +
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
 +
| style="background-color:#1a9851" |Phase III (E)
 +
|Physician's choice of:<br> 1. Capecitabine<br> 2. Eribulin<br> 3. Gemcitabine<br> 4. Vinorelbine
 +
| style="background-color:#1a9850" |Superior PFS
 +
|-
 +
|}
 +
====Chemotherapy====
 +
*[[Talazoparib (Talzenna)]] 1 mg PO once per day
 +
 +
'''Continued indefinitely'''
 +
 +
===References===
 +
# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://www.nejm.org/doi/full/10.1056/NEJMoa1802905 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30110579 PubMed]
  
 
=Additional resources=
 
=Additional resources=

Revision as of 02:17, 17 October 2018

Section editor transclusions

10 regimens on this page
13 variants on this page

Note: this page has regimens which are specific to breast cancer that is BRCA-mutated. Please see the main breast cancer page for other chemotherapy regimens.


Guidelines

ESMO

Advanced or metastatic disease, all lines of therapy

Olaparib monotherapy

back to top

Variant #1, 100 mg BID

Study Evidence
Tutt et al. 2010 Phase II

Chemotherapy

Continued indefinitely

Variant #2, 300 mg BID

Study Evidence Comparator Efficacy
Robson et al. 2017 (OlympiAD) Phase III (E) 1. Capecitabine
2. Eribulin
3. Vinorelbine 		Superior PFS

Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.

Chemotherapy

Continued indefinitely

Variant #3, 400 mg BID

Study Evidence
Tutt et al. 2010 Phase II
Kaufman et al. 2014 Phase II

Patients in Kaufman et al. 2014 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.

Chemotherapy

Continued indefinitely

References

  1. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. link to original article PubMed
  2. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed
  3. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed

Talazoparib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence Comparator Efficacy
Litton et al. 2018 (EMBRACA) Phase III (E) Physician's choice of:
1. Capecitabine
2. Eribulin
3. Gemcitabine
4. Vinorelbine 		Superior PFS

Chemotherapy

Continued indefinitely

References

  1. EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains protocol PubMed

Additional resources

Retrieved from "https://hemonc.org/w/index.php?title=Breast_cancer,_BRCA-mutated&oldid=32030"